Litcius/Paper detail

LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study

Laurence Albigès, Brian I. Rini, Katriina Peltola, G.A. De Velasco Oria, Mauricio Burotto, C. Suarez Rodriguez, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, M. Gumus, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, B. Venugopal, Andrew Z. Wang, R. Perini, Donna Vickery, T.B. Powles, Toni K. Choueiri

2023Annals of Oncology53 citationsDOIOpen Access PDF

Topics & Concepts

MedicineEverolimusClear cell renal cell carcinomaRenal cell carcinomaOncologyInternal medicineOpen labelPhases of clinical researchRandomized controlled trialClinical trialRenal cell carcinoma treatmentCancer, Hypoxia, and MetabolismRenal and related cancers
LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study | Litcius